+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Etravirine Market by Product Type, Application, Distribution Channel, Patient Age Group - Global Forecast 2025-2030- Product Image
Etravirine Market by Product Type, Application, Distribution Channel, Patient Age Group - Global Forecast 2025-2030- Product Image
Sale

Etravirine Market by Product Type, Application, Distribution Channel, Patient Age Group - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 192 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6015385
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Etravirine Market grew from USD 251.67 million in 2023 to USD 257.34 million in 2024. It is expected to continue growing at a CAGR of 3.34%, reaching USD 316.78 million by 2030.

Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in the treatment of HIV-1 infection in combination with other antiretrovirals. The necessity for Etravirine stems from its ability to resist strains of HIV resistant to first-generation NNRTIs, addressing a critical need for effective long-term management of HIV infection. The application of Etravirine is particularly pivotal in treatment-experienced patients, delivering higher efficacy in antiretroviral therapy regimens. The end-use scope includes healthcare settings such as hospitals, specialized HIV clinics, and pharmacies providing outpatient care. Market insights indicate that the demand for Etravirine is influenced by increasing HIV prevalence, expanded treatment guidelines, and advancements in HIV care, which have broadened its application. The latest opportunities reside in expanding access in emerging markets and integrating Etravirine into combination therapies with novel mechanisms of action. However, the market faces limitations due to patent expiry leading to generic competition, potential side effects, and patient adherence challenges. To leverage market potential, innovation can be directed towards enhancing drug formulations, focusing on once-daily dosing regimens, and developing fixed-dose combinations to improve patient compliance. Challenges such as regulatory hurdles and pricing pressures need to be mitigated through strategic alliances and partnerships with healthcare providers and policymakers. The nature of the Etravirine market is competitive, characterized by a mix of established companies and new entrants seeking to capitalize on unmet needs. Strategic recommendations include investing in research to explore additional therapeutic uses beyond HIV, utilizing digital health technologies for patient monitoring, and engaging in community outreach to boost awareness and adoption. Collaboration with stakeholders can drive advancements and support innovation to sustain market growth and effectively manage HIV treatment paradigms.

Understanding Market Dynamics in the Etravirine Market

The Etravirine Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing prevalence of HIV infections globally
    • Growing awareness and early diagnosis of HIV increasing need for effective treatments
    • Government initiatives and funding supporting HIV treatment research and accessibility
  • Market Restraints
    • Environmental challenges associated with expiry of etravirine
  • Market Opportunities
    • Emerging therapeutic potentials of etravirine in rare infectious diseases beyond HIV treatment
    • Expanding etravirine's applications in pediatric HIV care for improving long-term outcomes
  • Market Challenges
    • Economic and healthcare infrastructure disparities affecting patient access to etravirine in developing regions

Exploring Porter’s Five Forces for the Etravirine Market

Porter’s Five Forces framework further strengthens the insights of the Etravirine Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Etravirine Market

External macro-environmental factors deeply influence the performance of the Etravirine Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Etravirine Market

The Etravirine Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Etravirine Market

The Etravirine Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Etravirine Market

The Etravirine Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Etravirine Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amgen Inc., Aurobindo Pharma Ltd., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cipla Limited, Dr. Reddy's Laboratories, Eli Lilly and Company, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Glenmark Limited, Hetero Labs Limited, Janssen Global Services, LLC, Matrix Laboratories, Merck & Co., Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc., and ViiV Healthcare group of companies.

Market Segmentation & Coverage

This research report categorizes the Etravirine Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Product Type
    • Dosage
      • 100 mg
      • 200 mg
      • 25 mg
    • Formulations
      • Oral Solution
      • Suspension
      • Tablets
  • Application
    • HIV Treatment
      • First-line Therapy
      • Second-line Therapy
      • Third-line Therapy
    • PEP (Post-exposure Prophylaxis)
    • PrEP (Pre-exposure Prophylaxis)
  • Distribution Channel
    • Hospitals
      • Inpatient Pharmacies
      • Outpatient Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Patient Age Group
    • Adult
    • Geriatric
    • Pediatric
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of HIV infections globally
5.1.1.2. Growing awareness and early diagnosis of HIV increasing need for effective treatments
5.1.1.3. Government initiatives and funding supporting HIV treatment research and accessibility
5.1.2. Restraints
5.1.2.1. Environmental challenges associated with expiry of etravirine
5.1.3. Opportunities
5.1.3.1. Emerging therapeutic potentials of etravirine in rare infectious diseases beyond HIV treatment
5.1.3.2. Expanding etravirine's applications in pediatric HIV care for improving long-term outcomes
5.1.4. Challenges
5.1.4.1. Economic and healthcare infrastructure disparities affecting patient access to etravirine in developing regions
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Etravirine Market, by Product Type
6.1. Introduction
6.2. Dosage
6.2.1. 100 mg
6.2.2. 200 mg
6.2.3. 25 mg
6.3. Formulations
6.3.1. Oral Solution
6.3.2. Suspension
6.3.3. Tablets
7. Etravirine Market, by Application
7.1. Introduction
7.2. HIV Treatment
7.2.1. First-line Therapy
7.2.2. Second-line Therapy
7.2.3. Third-line Therapy
7.3. PEP (Post-exposure Prophylaxis)
7.4. PrEP (Pre-exposure Prophylaxis)
8. Etravirine Market, by Distribution Channel
8.1. Introduction
8.2. Hospitals
8.2.1. Inpatient Pharmacies
8.2.2. Outpatient Pharmacies
8.3. Online Pharmacies
8.4. Retail Pharmacies
9. Etravirine Market, by Patient Age Group
9.1. Introduction
9.2. Adult
9.3. Geriatric
9.4. Pediatric
10. Americas Etravirine Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Etravirine Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Etravirine Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. ETRAVIRINE MARKET RESEARCH PROCESS
FIGURE 2. ETRAVIRINE MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ETRAVIRINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ETRAVIRINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ETRAVIRINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ETRAVIRINE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ETRAVIRINE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2030 (%)
FIGURE 13. GLOBAL ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS ETRAVIRINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS ETRAVIRINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES ETRAVIRINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES ETRAVIRINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC ETRAVIRINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC ETRAVIRINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ETRAVIRINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ETRAVIRINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. ETRAVIRINE MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. ETRAVIRINE MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ETRAVIRINE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ETRAVIRINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ETRAVIRINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ETRAVIRINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ETRAVIRINE MARKET DYNAMICS
TABLE 7. GLOBAL ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ETRAVIRINE MARKET SIZE, BY DOSAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ETRAVIRINE MARKET SIZE, BY 100 MG, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ETRAVIRINE MARKET SIZE, BY 200 MG, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ETRAVIRINE MARKET SIZE, BY 25 MG, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ETRAVIRINE MARKET SIZE, BY FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ETRAVIRINE MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ETRAVIRINE MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ETRAVIRINE MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ETRAVIRINE MARKET SIZE, BY FIRST-LINE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ETRAVIRINE MARKET SIZE, BY SECOND-LINE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ETRAVIRINE MARKET SIZE, BY THIRD-LINE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ETRAVIRINE MARKET SIZE, BY PEP (POST-EXPOSURE PROPHYLAXIS), BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ETRAVIRINE MARKET SIZE, BY PREP (PRE-EXPOSURE PROPHYLAXIS), BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ETRAVIRINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ETRAVIRINE MARKET SIZE, BY INPATIENT PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ETRAVIRINE MARKET SIZE, BY OUTPATIENT PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ETRAVIRINE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ETRAVIRINE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ETRAVIRINE MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ETRAVIRINE MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ETRAVIRINE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS ETRAVIRINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 50. ARGENTINA ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 54. BRAZIL ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 55. BRAZIL ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 56. BRAZIL ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 62. CANADA ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 63. CANADA ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 64. CANADA ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 65. CANADA ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 66. CANADA ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 67. CANADA ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 68. CANADA ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 69. CANADA ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 70. MEXICO ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 71. MEXICO ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 72. MEXICO ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 73. MEXICO ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 74. MEXICO ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 75. MEXICO ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. MEXICO ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 77. MEXICO ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES ETRAVIRINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 87. ASIA-PACIFIC ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 88. ASIA-PACIFIC ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 89. ASIA-PACIFIC ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 90. ASIA-PACIFIC ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 91. ASIA-PACIFIC ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 92. ASIA-PACIFIC ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 93. ASIA-PACIFIC ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 94. ASIA-PACIFIC ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 95. ASIA-PACIFIC ETRAVIRINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 96. AUSTRALIA ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 97. AUSTRALIA ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 98. AUSTRALIA ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 99. AUSTRALIA ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 100. AUSTRALIA ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 101. AUSTRALIA ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. AUSTRALIA ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 103. AUSTRALIA ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 104. CHINA ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 105. CHINA ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 106. CHINA ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 107. CHINA ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 108. CHINA ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 109. CHINA ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. CHINA ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 111. CHINA ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 112. INDIA ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 113. INDIA ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 114. INDIA ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 115. INDIA ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 116. INDIA ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 117. INDIA ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. INDIA ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 119. INDIA ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 120. INDONESIA ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 121. INDONESIA ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 122. INDONESIA ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 123. INDONESIA ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 124. INDONESIA ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 125. INDONESIA ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. INDONESIA ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 127. INDONESIA ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 128. JAPAN ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 129. JAPAN ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 130. JAPAN ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 131. JAPAN ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 132. JAPAN ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 133. JAPAN ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. JAPAN ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 135. JAPAN ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 136. MALAYSIA ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 137. MALAYSIA ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 138. MALAYSIA ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 139. MALAYSIA ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 140. MALAYSIA ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 141. MALAYSIA ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. MALAYSIA ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 143. MALAYSIA ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 144. PHILIPPINES ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 145. PHILIPPINES ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 146. PHILIPPINES ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 147. PHILIPPINES ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 148. PHILIPPINES ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 149. PHILIPPINES ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. PHILIPPINES ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 151. PHILIPPINES ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 152. SINGAPORE ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 153. SINGAPORE ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 154. SINGAPORE ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 155. SINGAPORE ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 156. SINGAPORE ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 157. SINGAPORE ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. SINGAPORE ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 159. SINGAPORE ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 160. SOUTH KOREA ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 161. SOUTH KOREA ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 162. SOUTH KOREA ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 163. SOUTH KOREA ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 164. SOUTH KOREA ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 165. SOUTH KOREA ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. SOUTH KOREA ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 167. SOUTH KOREA ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 168. TAIWAN ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 169. TAIWAN ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 170. TAIWAN ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 171. TAIWAN ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 172. TAIWAN ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 173. TAIWAN ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. TAIWAN ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 175. TAIWAN ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 176. THAILAND ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 177. THAILAND ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 178. THAILAND ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 179. THAILAND ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 180. THAILAND ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 181. THAILAND ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. THAILAND ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 183. THAILAND ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 184. VIETNAM ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 185. VIETNAM ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 186. VIETNAM ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 187. VIETNAM ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 188. VIETNAM ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 189. VIETNAM ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. VIETNAM ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 191. VIETNAM ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA ETRAVIRINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 201. DENMARK ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 202. DENMARK ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 203. DENMARK ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 204. DENMARK ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 205. DENMARK ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 206. DENMARK ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 207. DENMARK ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 208. DENMARK ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 209. EGYPT ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 210. EGYPT ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 211. EGYPT ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 212. EGYPT ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 213. EGYPT ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 214. EGYPT ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 215. EGYPT ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 216. EGYPT ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 217. FINLAND ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 218. FINLAND ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 219. FINLAND ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 220. FINLAND ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 221. FINLAND ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 222. FINLAND ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 223. FINLAND ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 224. FINLAND ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 225. FRANCE ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 226. FRANCE ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 227. FRANCE ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 228. FRANCE ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 229. FRANCE ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 230. FRANCE ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 231. FRANCE ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 232. FRANCE ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 233. GERMANY ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 234. GERMANY ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 235. GERMANY ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 236. GERMANY ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 237. GERMANY ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 238. GERMANY ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 239. GERMANY ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 240. GERMANY ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 241. ISRAEL ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 242. ISRAEL ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 243. ISRAEL ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 244. ISRAEL ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 245. ISRAEL ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 246. ISRAEL ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 247. ISRAEL ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 248. ISRAEL ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 249. ITALY ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 250. ITALY ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 251. ITALY ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 252. ITALY ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 253. ITALY ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 254. ITALY ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 255. ITALY ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 256. ITALY ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 257. NETHERLANDS ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 258. NETHERLANDS ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 259. NETHERLANDS ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 260. NETHERLANDS ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 261. NETHERLANDS ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 262. NETHERLANDS ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 263. NETHERLANDS ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 264. NETHERLANDS ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 265. NIGERIA ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 266. NIGERIA ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 267. NIGERIA ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 268. NIGERIA ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 269. NIGERIA ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 270. NIGERIA ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 271. NIGERIA ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 272. NIGERIA ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 273. NORWAY ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 274. NORWAY ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 275. NORWAY ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 276. NORWAY ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 277. NORWAY ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 278. NORWAY ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 279. NORWAY ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 280. NORWAY ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 281. POLAND ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 282. POLAND ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 283. POLAND ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 284. POLAND ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 285. POLAND ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 286. POLAND ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 287. POLAND ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 288. POLAND ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 289. QATAR ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 290. QATAR ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 291. QATAR ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 292. QATAR ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 293. QATAR ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 294. QATAR ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 295. QATAR ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 296. QATAR ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 297. RUSSIA ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 298. RUSSIA ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 299. RUSSIA ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 300. RUSSIA ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 301. RUSSIA ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 302. RUSSIA ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 303. RUSSIA ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 304. RUSSIA ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 306. SAUDI ARABIA ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 308. SAUDI ARABIA ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 310. SAUDI ARABIA ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 311. SAUDI ARABIA ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 312. SAUDI ARABIA ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 313. SOUTH AFRICA ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 314. SOUTH AFRICA ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 315. SOUTH AFRICA ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 316. SOUTH AFRICA ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 318. SOUTH AFRICA ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 319. SOUTH AFRICA ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 320. SOUTH AFRICA ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 321. SPAIN ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 322. SPAIN ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 323. SPAIN ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 324. SPAIN ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 325. SPAIN ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 326. SPAIN ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 327. SPAIN ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 328. SPAIN ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 329. SWEDEN ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 330. SWEDEN ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 331. SWEDEN ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 332. SWEDEN ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 333. SWEDEN ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 334. SWEDEN ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 335. SWEDEN ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 336. SWEDEN ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 337. SWITZERLAND ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 338. SWITZERLAND ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 339. SWITZERLAND ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 340. SWITZERLAND ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 341. SWITZERLAND ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 342. SWITZERLAND ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 343. SWITZERLAND ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 344. SWITZERLAND ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 345. TURKEY ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 346. TURKEY ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 347. TURKEY ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 348. TURKEY ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 349. TURKEY ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 350. TURKEY ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 351. TURKEY ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 352. TURKEY ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 353. UNITED ARAB EMIRATES ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 354. UNITED ARAB EMIRATES ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 355. UNITED ARAB EMIRATES ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 356. UNITED ARAB EMIRATES ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 357. UNITED ARAB EMIRATES ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 358. UNITED ARAB EMIRATES ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 359. UNITED ARAB EMIRATES ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 360. UNITED ARAB EMIRATES ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 361. UNITED KINGDOM ETRAVIRINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 362. UNITED KINGDOM ETRAVIRINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 363. UNITED KINGDOM ETRAVIRINE MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 364. UNITED KINGDOM ETRAVIRINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 365. UNITED KINGDOM ETRAVIRINE MARKET SIZE, BY HIV TREATMENT, 2018-2030 (USD MILLION)
TABLE 366. UNITED KINGDOM ETRAVIRINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 367. UNITED KINGDOM ETRAVIRINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 368. UNITED KINGDOM ETRAVIRINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 369. ETRAVIRINE MARKET SHARE, BY KEY PLAYER, 2023
TABLE 370. ETRAVIRINE MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Etravirine Market, which are profiled in this report, include:
  • Abbott Laboratories
  • Amgen Inc.
  • Aurobindo Pharma Ltd.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Glenmark Limited
  • Hetero Labs Limited
  • Janssen Global Services, LLC
  • Matrix Laboratories
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • ViiV Healthcare group of companies

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages192
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 257.34 Million
Forecasted Market Value ( USD ) by 2030 $ 316.78 Million
Compound Annual Growth Rate3.3%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Etravirine (CAS 269055-15-4) Global Market Research Report 2024 - Product Image

Etravirine (CAS 269055-15-4) Global Market Research Report 2024

  • Report
  • 50 Pages
  • Global
From
Anti-Retroviral Drugs Market by Drug Class:, Route of Administration, Application, Distribution Channel - Global Forecast 2025-2030 - Product Image

Anti-Retroviral Drugs Market by Drug Class:, Route of Administration, Application, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 192 Pages
  • Global
From
Human Immunodeficiency Virus Therapeutics Market by Drug Class, End-User, Distribution Channel - Global Forecast 2025-2030 - Product Image

Human Immunodeficiency Virus Therapeutics Market by Drug Class, End-User, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
HIV Drugs - Global Strategic Business Report - Product Image

HIV Drugs - Global Strategic Business Report

  • Report
  • 164 Pages
  • Global
From
Fusion Inhibitors Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024-2032 - Product Image

Fusion Inhibitors Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024-2032

  • Report
  • 118 Pages
  • Global
From

About the Etravirine Market

Etravirine is an antiretroviral drug used to treat HIV/AIDS. It is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that works by blocking the action of the HIV-1 reverse transcriptase enzyme, which is responsible for the replication of the virus. Etravirine is used in combination with other antiretroviral drugs to treat HIV-1 infection in adults and adolescents over the age of 12. It is also used to treat HIV-1 infection in adults and adolescents over the age of 12 who have already been treated with other antiretroviral drugs. Etravirine is available in tablet form and is taken orally. It is usually taken twice daily with food. Common side effects of etravirine include nausea, headache, and dizziness. More serious side effects may include liver problems, changes in body fat, and changes in the immune system. Etravirine is marketed by several pharmaceutical companies, including Janssen Pharmaceuticals, Merck & Co., and Tibotec Pharmaceuticals. It is also available in generic form from several generic drug manufacturers. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.